Currently, while preclinical mechanistic data support the utility of HDAC inhibition in multiple breast cancer subtypes via the unique mechanisms described above and elsewhere, HDAC inhibition is not an approved therapeutic modality for the treatment of breast cancer. This evidence concerns the gene HDAC9 and breast cancer.